AIM ImmunoTech Inc
AMEX:AIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AIM ImmunoTech Inc
Revenue
AIM ImmunoTech Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AIM ImmunoTech Inc
AMEX:AIM
|
Revenue
$88k
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$61.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$36.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$12B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
AIM ImmunoTech Inc
Glance View
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The firm's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.
See Also
What is AIM ImmunoTech Inc's Revenue?
Revenue
88k
USD
Based on the financial report for Dec 31, 2025, AIM ImmunoTech Inc's Revenue amounts to 88k USD.
What is AIM ImmunoTech Inc's Revenue growth rate?
Revenue CAGR 10Y
-4%
Over the last year, the Revenue growth was -48%. The average annual Revenue growth rates for AIM ImmunoTech Inc have been -15% over the past three years , -12% over the past five years , and -4% over the past ten years .